David's mailing address filed with the SEC is C/O CULLINAN THERAPEUTICS, INC., ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142.
Over the last 4 years, insiders at Cullinan Oncology have traded over 29,405,190$ worth of Cullinan Oncology stock and bought 2,950,136 units worth 38,299,215$ . The most active insiders traders include Partners L P/Ilbiotechnolog...、Ansbert Gadicke、Morana Jovan Embiricos. On average, Cullinan Oncology executives and independent directors trade stock every 14 days with the average trade being worth of 914,589$. The most recent stock trade was executed by Jennifer Michaelson on 5 September 2024, trading 8,000 units of CGEM stock currently worth 144,720$.
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Cullinan Oncology executives and other stock owners filed with the SEC include: